Boston Scientific (NYSE:BSX) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Boston Scientific (NYSE:BSX) from a buy rating to a hold rating in a report released on Saturday.

BSX has been the topic of several other reports. The Goldman Sachs Group reduced their price objective on Boston Scientific from $98.00 to $93.00 and set a “buy” rating on the stock in a research note on Friday. Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Morgan Stanley decreased their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Barclays lowered their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $106.00.

Boston Scientific Stock Down 1.4%

Shares of BSX opened at $69.21 on Friday. Boston Scientific has a one year low of $67.56 and a one year high of $109.50. The company has a market cap of $102.86 billion, a P/E ratio of 35.68, a P/E/G ratio of 1.07 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $77.45 and a two-hundred day simple moving average of $90.71.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. increased its position in Boston Scientific by 70.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 595,938 shares of the medical equipment provider’s stock valued at $56,823,000 after acquiring an additional 247,097 shares during the period. Bank of New Hampshire grew its stake in shares of Boston Scientific by 2.4% in the fourth quarter. Bank of New Hampshire now owns 22,159 shares of the medical equipment provider’s stock worth $2,113,000 after purchasing an additional 523 shares during the last quarter. World Investment Advisors increased its holdings in Boston Scientific by 2.2% in the fourth quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock valued at $1,846,000 after purchasing an additional 411 shares during the period. Farmers National Bank bought a new position in Boston Scientific during the 4th quarter worth $204,000. Finally, Corient Private Wealth LLC raised its position in Boston Scientific by 2.6% during the 4th quarter. Corient Private Wealth LLC now owns 224,554 shares of the medical equipment provider’s stock worth $21,437,000 after purchasing an additional 5,756 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Goldman Sachs trimmed its price target from $98 to $93 but kept a “buy” rating, which signals continued institutional confidence and still implies material upside from current levels. Goldman Sachs price target note
• Neutral Sentiment: Coverage/valuation context: a recent writeup notes analysts are tightening growth/execution assumptions and modestly lowering fair‑value estimates, reflecting a gradual reset rather than a structural change in the business. Why The Narrative Around Boston Scientific Is Shifting
• Neutral Sentiment: Erste Group trimmed its FY2027 EPS forecast very slightly (from $3.92 to $3.91), a minor estimate tweak that suggests analysts are incrementally lowering near‑term assumptions but not cutting guidance aggressively. Erste Group estimate update
• Negative Sentiment: A broad flurry of law firms and investor‑rights groups (Glancy Prongay Wolke & Rotter, The Gross Law Firm, Faruqi & Faruqi, Rosen, Pomerantz, Portnoy, Bernstein Liebhard and others) have issued class‑action notices and investor alerts alleging misrepresentations tied to the July 23, 2025–Feb 3, 2026 class period; they’re soliciting lead‑plaintiff candidates with a May 4, 2026 deadline — the sheer volume of filings/alerts is creating headline pressure and increases the risk of litigation expense, management distraction, and potential settlement/awards. Representative notices: PR Newswire – Glancy notice GlobeNewsWire – Gross Law Firm Newsfile – Faruqi & Faruqi

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.